PD 198306

SKU: orb1306133

Description

PD 198306 is a selective MEK inhibitor exhibiting antihyperalgesic properties. It effectively attenuates the Streptozocin-induced elevation of active ERK1 levels, making it a useful research tool for studying MAPK/ERK signaling in diabetic neuropathy models both in vitro and in vivo.

Research Area

Signal Transduction

Key Properties

• CAS Number: 212631-61-3
• MW: 476.23
• Purity: 99.75% (May vary between batches)
• Formula: C₁₈H₁₆F₃IN₂O₂
• SMILES: N(C1=C(C(NOCC2CC2)=O)C=C(F)C(F)=C1F)C3=C(C)C=C(I)C=C3
• Target: MEK
• Solubility: DMSO:45 mg/mL (94.49 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (10.5 mM)

Bioactivity

• In Vivo:
  In male Sprague Dawley rats bearing neuropathic pain, PD 198306 (1-30 μg/10 μL; i.t.) dose-dependently blocks static allodynia in both the chronic constriction injury and the streptozocin models.
• In Vitro:
  PD 198306 (10 μM) reduces Tha-Crimson replication by 30% at 18 h and 50% at 36 h. PD 198306 (10 μM) significantly inhibits Tha-GFP replication by 25%.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

rabies, phosphatases, phosphate, screening, RNA, antihyperalgesic, drug, inhibit, Inhibitor, kinases, neuropathic, Mitogen-activated protein kinase kinase, mitogen-activated protein, PD 198306, PD198306, PD-198306, pain, ERK, inositol, interference, MAPK, MAP2K, MAPKK, MEK

Compound Identifiers

PubChem CID

9956637